Vedolizumab as induction and maintenance therapy for Crohn's disease.
Explore this paper's citation graph
Summary
Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52.
- Type
- article
- Published
- 2013-08-21
- Cited by
- 2,105
- References
- 51
- Access
- Open access
- OpenAlex
- https://openalex.org/W2077531651
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:38285939
Keywords
Vedolizumab, Maintenance therapy, Crohn's disease, Induction therapy, Medicine
References
- Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials.
- Use of thiopurines in inflammatory bowel disease: Safety issues.
- Long‐term safety of ustekinumab in patients with moderate‐to‐severe psoriasis: final results from 5 years of follow‐up
- Seroepidemiology of Human Polyomaviruses
- Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
- Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin.
- Evaluation of the Incidence of Anti-JC Virus Antibodies in a Cohort of Natalizumab-Treated Patients
- Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
- Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
- Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
- Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose‐ranging Study
- Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.
- Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy.
- A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
- Antibodies to JC and BK viruses among persons with non‐Hodgkin lymphoma
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
- Maintenance treatment of Crohn's disease
- Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease
- A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease.
- Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy.
Cited by
- Management of Crohn’s disease in poor responders to adalimumab
- Risk of infections with biological agents.
- The gut microbiota and inflammatory bowel disease
- Angiogenesis-related proteins--their role in the pathogenesis and treatment of inflammatory bowel disease.
- Anti-TNF-Biosimilars bei chronisch entzündlichen Darmerkrankungen
- Specific immunotherapy ameliorates ulcerative colitis
- Informatics-Based Discovery of Disease-Associated Immune Profiles
- Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound
- A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
- Pneumocystis jirovecii Pneumonia in Pediatric Inflammatory Bowel Disease: A Case Report and Literature Review
- Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab‐treated patients
- Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
- Predictive Models of Therapeutic Response to Vedolizumab: A Novel Step into Personalized Medicine in Crohn's Disease?
- Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials
- Protein Tyrosine Phosphatases: Regulators of CD4 T Cells in Inflammatory Bowel Disease
- Targeting Interleukin-23 in the Treatment of Noninfectious Uveitis
- Recent Advances in Aptamer Discovery and Applications
- Efficacy of Vedolizumab for Inflammatory Bowel Disease in the Setting of DiGeorge Syndrome.
- Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases
- Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease.
Related papers
- Mo1217 Effects of Continued Vedolizumab Therapy for Crohn's Disease in Week 6 Induction Therapy Nonresponders
- Tu1905: IMPROVED HISTO-ENDOSCOPIC OUTCOMES WITH VEDOLIZUMAB IN EARLY VERSUS LATE CROHN’S DISEASE REGARDLESS OF DISEASE LOCATION: INSIGHTS FROM THE LOVE-CD TRIAL
- Mo1845 - Higher Serum Concentrations of Vedolizumab are Associated with Superior Endoscopic Outcomes in Crohn's Disease: Data from the Love-CD Trial
- Vedolizumab in Crohn Disease genesis-sefh drug evaluation report* Vedolizumab en Enfermedad de Crohn; Informe de evaluación GENESIS-SEFH
- Tu1268 Effect of Vedolizumab on Health-Related Quality of Life in Patients With Crohn's Disease
- Treatment of complicated Crohn's disease with vedolizumab
- Tu1925: CLINICAL AND ENDOSCOPIC EFFECTIVENESS OF VEDOLIZUMAB IN PATIENTS WITH ILEAL CROHN’S DISEASE
- Tu1359 Efficacy of Vedolizumab As Induction Therapy in Refractory IBD Patients Following Multiple Anti-TNF Therapy Failures
- Vedolizumab for induction and maintenance of remission in Crohn’s disease